Efficacy of corticosteroids in immunoglobulin A nephropathy with less than 25% crescents

  • Jingjing Chen
  • Hui XuEmail author
  • Zhangzhe Peng
  • Lizhen Lin
  • Cuifang Li
  • Xuejing Zhu
  • Shao LiuEmail author
Original article



Crescent formation in immunoglobulin A nephropathy (IgAN) has been demonstrated to be a risk factor for worse outcomes. For IgAN patients with 0–25% crescentic glomeruli (C1), whether corticosteroids (CS) can improve the prognosis remains unclear. We tried to investigate the need for using CS in IgAN patients with C1 in different proteinuria levels.


A total of 120 eligible IgAN patients with C1 from two academic medical centers were retrospectively studied, and 57 (47.5%) received CS. Patients were grouped according to with or without CS. The outcomes were the rate of estimated glomerular filtration rate (eGFR) decline (ml/min per 1.73 m2/year) and a composite outcome (50% decrease in eGFR, end stage renal disease (ESRD) or death due to kidney disease). The progression of adverse outcome among them were analyzed in Kaplan–Meier curve. The independent significance of CS on renal outcome or eGFR decline rate were analyzed by multivariable Cox regression or linear regression.


Unadjusted Kaplan–Meier showed that the outcome of treated patients was better than that of the untreated patients. Multiple Cox regression and linear regression analysis found that CS independently protected the renal outcome and decreased the eGFR decline rate. In the subgroup analysis, multivariate linear regression showed that CS decreased the eGFR decline rate both in proteinuria ≥ 1 g/day and < 1 g/day.


CS protected the renal outcome and slowed the eGFR decline rate of IgAN patients with C1, it also decreased the eGFR decline rate even in those with initial proteinuria < 1 g/day.


Crescent Immunoglobulin A nephropathy Prognosis Corticosteroids Estimated glomerular filtration rate (eGFR) 



This work was funded by the Natural Science Foundation of Hunan Province, China [Grant number 2018JJ3835].

Compliance with ethical standards

Conflicts of interest

The authors have declared that no conflict of interest exists.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the Ethics Committee (Central South University, No. 2018121134) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Supplementary material

10157_2019_1795_MOESM1_ESM.pdf (115 kb)
Supplementary file1 (PDF 115 kb)
10157_2019_1795_MOESM2_ESM.pdf (82 kb)
Supplementary file2 (PDF 81 kb)
10157_2019_1795_MOESM3_ESM.pdf (81 kb)
Supplementary file3 (PDF 80 kb)


  1. 1.
    Roberts IS. Pathology of IgA nephropathy. Nat Rev Nephrol. 2014;10:445–54.CrossRefGoogle Scholar
  2. 2.
    Coppo R. Clinical and histological risk factors for progression of IgA nephropathy: an update in children, young and adult patients. J Nephrol. 2017;30:339–46.CrossRefGoogle Scholar
  3. 3.
    Coppo R. Treatment of IgA nephropathy: recent advances and prospects. Nephrol Ther. 2018;14(Suppl 1):S13–21.CrossRefGoogle Scholar
  4. 4.
    Lv J, Xu D, Perkovic V, Ma X, Johnson DW, Woodward M, et al. Corticosteroid therapy in IgA nephropathy. J Am Soc Nephrol. 2012;23:1108–16.CrossRefGoogle Scholar
  5. 5.
    Yang D, He L, Peng X, Liu H, Peng Y, Yuan S, et al. The efficacy of tonsillectomy on clinical remission and relapse in patients with IgA nephropathy: a randomized controlled trial. Ren Fail. 2016;38:242–8.CrossRefGoogle Scholar
  6. 6.
    Radhakrishnan J, Cattran DC. The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines–application to the individual patient. Kidney Int. 2012;82:840–56.CrossRefGoogle Scholar
  7. 7.
    Rasche FM, Keller F, Rasche WG, Schiekofer S, Boldt A, Sack U, et al. Why, when and how should immunosuppressive therapy considered in patients with immunoglobulin A nephropathy? Clin Exp Immunol. 2016;186:115–33.CrossRefGoogle Scholar
  8. 8.
    Tesar V, Troyanov S, Bellur S, Verhave JC, Cook HT, Feehally J, et al. Corticosteroids in IgA nephropathy: a retrospective analysis from the VALIGA study. J Am Soc Nephrol. 2015;26:2248–58.CrossRefGoogle Scholar
  9. 9.
    Moroni G, Ponticelli C. Rapidly progressive crescentic glomerulonephritis: early treatment is a must. Autoimmun Rev. 2014;13:723–9.CrossRefGoogle Scholar
  10. 10.
    Chen S, Tang Z, Xiang H, Li X, Chen H, Zhang H, et al. Etiology and outcome of crescentic glomerulonephritis from a single center in China: a 10-year review. Am J Kidney Dis. 2016;67:376–83.CrossRefGoogle Scholar
  11. 11.
    Cai F, Han F, Wang H, Han H, Le J, Lan L, et al. The crescentic implication of renal outcomes in proliferative lupus nephritis. J Rheumatol. 2018;45:513–20.CrossRefGoogle Scholar
  12. 12.
    Rianthavorn P, Chacranon M. Long-term renal outcome in pediatric glomerulonephritis associated with crescent formation. Clin Exp Nephrol. 2018;22:661–7.CrossRefGoogle Scholar
  13. 13.
    Zhang X, Shi S, Ouyang Y, Yang M, Shi M, Pan X, et al. A validation study of crescents in predicting ESRD in patients with IgA nephropathy. J Transl Med. 2018;16:115.CrossRefGoogle Scholar
  14. 14.
    Park S, Baek CH, Cho H, Yu MY, Kim YC, Go H, et al. Glomerular crescents are associated with worse graft outcome in allograft IgA nephropathy. Am J Transpl. 2018;19:145–55.CrossRefGoogle Scholar
  15. 15.
    Tanaka Y, Nakashima Y, Mima T, Ohya M, Yamamoto S, Kobayashi S, et al. Effects of cyclophosphamide pulse therapy on the clinical and histopathological findings, particularly crescent formation, in a patient with adult-onset steroid-refractory Henoch-Schonlein purpura nephritis. Intern Med. 2015;54:2207–11.CrossRefGoogle Scholar
  16. 16.
    Zhang W, Yuan M, Hong L, Zhou Q, Chen W, Yang S, et al. Clinical outcomes of lupus nephritis patients with different proportions of crescents. Lupus. 2016;25:1532–41.CrossRefGoogle Scholar
  17. 17.
    Trimarchi H, Barratt J, Cattran DC, Cook HT, Coppo R, Haas M, et al. Oxford classification of IgA nephropathy 2016: an update from the IgA nephropathy classification working group. Kidney Int. 2017;91:1014–21.CrossRefGoogle Scholar
  18. 18.
    Lv J, Zhang H, Wong MG, Jardine MJ, Hladunewich M, Jha V, et al. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA. 2017;318:432–42.CrossRefGoogle Scholar
  19. 19.
    Barnes PJ. Glucocorticoids. Chem Immunol Allergy. 2014;100:311–6.CrossRefGoogle Scholar
  20. 20.
    Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AR, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.CrossRefGoogle Scholar
  21. 21.
    He W, Liu Y, Feng J, Huang Q, Xu J, Liu X, et al. The Epidemiological characteristics of stroke in Hunan Province. China Front Neurol. 2018;9:583.CrossRefGoogle Scholar
  22. 22.
    Gatta A, Verardo A, Bolognesi M. Hypoalbuminemia. Intern Emerg Med. 2012;7(Suppl 3):S193–S199199.CrossRefGoogle Scholar
  23. 23.
    Zeng C, Wang YL, Wei J, Yang T, Li H, Xie DX, et al. Association between low serum magnesium concentration and hyperuricemia. Magnes Res. 2015;28:56–63.PubMedGoogle Scholar
  24. 24.
    Liu H, Peng Y, Liu H, Liu Y, Yuan S, Liu F, et al. Renal biopsy findings of patients presenting with isolated hematuria: disease associations. Am J Nephrol. 2012;36:377–85.CrossRefGoogle Scholar
  25. 25.
    Smeets B, Uhlig S, Fuss A, Mooren F, Wetzels JF, Floege J, et al. Tracing the origin of glomerular extracapillary lesions from parietal epithelial cells. J Am Soc Nephrol. 2009;20:2604–15.CrossRefGoogle Scholar
  26. 26.
    Cattran DC, Coppo R, Cook HT, Feehally J, Roberts IS, Troyanov S, et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009;76:534–45.CrossRefGoogle Scholar
  27. 27.
    Rauen T, Eitner F, Fitzner C, Sommerer C, Zeier M, Otte B, et al. Intensive supportive care plus Immunosuppression in IgA nephropathy. N Engl J Med. 2015;373:2225–36.CrossRefGoogle Scholar
  28. 28.
    Homik J, Suarez-Almazor ME, Shea B, Cranney A, Wells G, Tugwell P. Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst Rev. 2000; D952.Google Scholar
  29. 29.
    Erkan E. Proteinuria and progression of glomerular diseases. Pediatr Nephrol. 2013;28:1049–58.CrossRefGoogle Scholar
  30. 30.
    Borrego J, Mazuecos A, Gentil MA, Cabello M, Rodriguez A, Osuna A, et al. Proteinuria as a predictive factor in the evolution of kidney transplantation. Transpl Proc. 2013;45:3627–9.CrossRefGoogle Scholar
  31. 31.
    Zhu X, Li H, Liu Y, You J, Qu Z, Yuan S, et al. Tubular atrophy/interstitial fibrosis scores of Oxford classification combinded with proteinuria level at biopsy provides earlier risk prediction in lgA nephropathy. Sci Rep. 2017;7:1100.CrossRefGoogle Scholar
  32. 32.
    Cravedi P, Remuzzi G. Pathophysiology of proteinuria and its value as an outcome measure in chronic kidney disease. Br J Clin Pharmacol. 2013;76:516–23.PubMedPubMedCentralGoogle Scholar

Copyright information

© Japanese Society of Nephrology 2019

Authors and Affiliations

  1. 1.Department of PharmacyXiangya Hospital of Central South UniversityChangshaPeople’s Republic of China
  2. 2.Department of NephrologyXiangya Hospital of Central South UniversityChangshaPeople’s Republic of China
  3. 3.Institute for Rational and Safe Medication PracticesNational Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South UniversityChangshaChina
  4. 4.Department of NutritionXiang’an Hospital of Xiamen UniversityXiamenChina
  5. 5.Department of NephrologyThe Second Xiangya Hospital, Central South UniversityChangshaChina

Personalised recommendations